Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5288726 | COSETTE | Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation |
Apr, 2017
(7 years ago) | |
US5288726 (Pediatric) | COSETTE | Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation |
Oct, 2017
(6 years ago) | |
US6693115 | COSETTE | Acid addition salts of hydropyridine derivatives |
Jul, 2021
(2 years ago) | |
US8404703 | COSETTE | Medicinal compositions containing aspirin |
Mar, 2022
(2 years ago) | |
US8569325 | COSETTE | Method of treatment with coadministration of aspirin and prasugrel |
Jan, 2023
(1 year, 4 months ago) | |
US8569325 (Pediatric) | COSETTE | Method of treatment with coadministration of aspirin and prasugrel |
Jul, 2023
(10 months ago) | |
US8404703 (Pediatric) | COSETTE | Medicinal compositions containing aspirin |
Jul, 2023
(10 months ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-182) | Jul 12, 2019 |
Pediatric Exclusivity(PED) | Jan 12, 2020 |
New Chemical Entity Exclusivity(NCE) | Jul 10, 2014 |
NCE-1 date: 12 January, 2019
Market Authorisation Date: 10 July, 2009
Treatment: Treatment or prophylaxis of thrombosis or embolisms; Use of prasugrel and aspirin in patients requiring the reduction of thrombotic cardiovascular events
Dosage: TABLET;ORAL